Literature DB >> 31147782

Influence of Hepatitis C virus coinfection on immune reconstitution in HIV subjects.

María Noel Badano1, Cecilia Parodi2, Natalia Aloisi2, Marcelo Corti3, María Marta Elizalde de Bracco2, Patricia Baré2.   

Abstract

Despite successful HIV suppression by antiretroviral treatment (ART), immune activation may persist in HIV patients, contributing to an impaired immunological reconstitution and disease progression. Information regarding Hepatitis C virus (HCV) coinfection as a factor that accounts for immune activation in HIV subjects remains unclear. Furthermore, most studies have been carried out considering HIV/HCV patients as a whole, without taking into account the presence or absence of liver damage. Therefore, it is unknown if HCV and/or its liver-related disease could act as two independent factors contributing to the immune activation. In this study, we investigated the presence of immune activation in a cohort of 50 HIV/HCV patients by measuring cytokine levels, CD4+ T-cell counts and CD4/CD8 ratios. Six patient groups were defined according to HIV viral load, HCV status, and liver disease to assess the impact of each of these factors on immune activation and reconstitution in HIV/HCV patients. Only subjects with controlled HIV infection and cleared HCV displayed immunological parameters within normal ranges. The mere presence of HCV contributes to immune activation leading to an inappropriate immunological reconstitution. This state exacerbates in the presence of HCV-associated liver disease. Our results suggest that ART is not enough to suppress immune activation in the context of HIV/HCV coinfection, since both HCV and its liver-related disease would contribute to the immune activation. Given that immune activation worsens immunological reconstitution and clinical status, these results support the priority of HCV treatment in HIV/HCV patients and suggest the monitoring of their liver status.

Entities:  

Keywords:  Antiretroviral treatment; HIV/HCV coinfection; Immune activation; Immunological reconstitution; Liver disease

Mesh:

Substances:

Year:  2019        PMID: 31147782     DOI: 10.1007/s00430-019-00619-4

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  36 in total

1.  CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause?

Authors:  Zvi Grossman; Martin Meier-Schellersheim; Ana E Sousa; Rui M M Victorino; William E Paul
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

Review 2.  Viral hepatitis in HIV infection.

Authors:  Margaret James Koziel; Marion G Peters
Journal:  N Engl J Med       Date:  2007-04-05       Impact factor: 91.245

3.  Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy.

Authors:  Martin Potter; Adefowope Odueyungbo; Hong Yang; Sahar Saeed; Marina B Klein
Journal:  AIDS       Date:  2010-07-31       Impact factor: 4.177

4.  Association of IL-10-promoter genetic variants with the rate of CD4 T-cell loss, IL-10 plasma levels, and breadth of cytotoxic T-cell lymphocyte response during chronic HIV-1 infection.

Authors:  Dshanta D Naicker; Bingxia Wang; Elena Losina; Jennifer Zupkosky; Susan Bryan; Shabashini Reddy; Manjeetha Jaggernath; Mammekwa Mokgoro; Philip J R Goulder; Daniel E Kaufmann; Thumbi Ndung'u
Journal:  Clin Infect Dis       Date:  2011-11-18       Impact factor: 9.079

5.  The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women's interagency HIV study.

Authors:  J A DeHovitz; A Kovacs; J G Feldman; K Anastos; M Young; M Cohen; S J Gange; S Melnick; R M Greenblatt
Journal:  J Infect Dis       Date:  2000-09-27       Impact factor: 5.226

6.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

7.  High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.

Authors:  Veronica D Gonzalez; Karolin Falconer; Kim G Blom; Olle Reichard; Birgitte Mørn; Alex Lund Laursen; Nina Weis; Annette Alaeus; Johan K Sandberg
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

Review 8.  TGF-β signalling and liver disease.

Authors:  Isabel Fabregat; Joaquim Moreno-Càceres; Aránzazu Sánchez; Steven Dooley; Bedair Dewidar; Gianluigi Giannelli; Peter Ten Dijke
Journal:  FEBS J       Date:  2016-02-22       Impact factor: 5.542

9.  CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use.

Authors:  J M Taylor; J L Fahey; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

10.  Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients.

Authors:  A H Mohsen; P J Easterbrook; C Taylor; B Portmann; R Kulasegaram; S Murad; M Wiselka; S Norris
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more
  1 in total

1.  Decreased Activated CD4+ T Cell Repertoire Diversity After Antiretroviral Therapy in HIV-1/HCV Coinfection Correlates with CD4+ T Cell Recovery.

Authors:  Nicole E Skinner; Candelaria Vergara; Ramy El-Diwany; Harry Paul; Alyza Skaist; Sarah J Wheelan; David L Thomas; Stuart C Ray; Ashwin Balagopal; Justin R Bailey
Journal:  Viral Immunol       Date:  2021-10-21       Impact factor: 2.175

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.